Recombinant Human PD-1

Recombinant Human PD-1

Product No.: P613

- -
- -
Target
PD-1
Alternate Names
PD1, PDCD1, CD279
Applications
ELISA
,
FA
,
SDS-PAGE
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Expression Host
HEK-293 Cells
Reconstitution
Reconstitute at 1mg/ml using filtered deionized water. Gently mix by vortexing and/or inversion for 5 minutes or until fully dissolved. Centrifuge if necessary.
State of Matter
Lyophilized
Storage and Handling
1 month, 2 to 8 °C under sterile conditions after opening and reconstituting.
1 year from date of receipt, -20 to -80 °C as supplied. 3 months from date of receipt, -20 to -80 °C sterile conditions after opening and reconstituting.
Regulatory Status
Research Use Only
Country of Origin
USA
Shipping
Ambient
Amino Acid Sequence
LDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQT
Applications and Recommended Usage?
Quality Tested by Leinco
SDS-PAGE,
WB,
ELISA,
FA
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Background
Human Programmed Death 1 (PD-1) is a receptor located on the surface of various cell types including T-cells, B-cells, and some myeloid cells 1 . Its primary function involves regulating the immune system by inhibiting T-cell activation. This process is crucial for promoting self-tolerance and minimizing autoimmune reactions. PD-1 interacts with its ligands, PD-L1 and PD-L2, to effectively suppress T-cell activation and the production of cytokines. This mechanism is frequently exploited by cancers as a means to evade the immune response 2, 3.

The interaction between PD-1 and PD-L1 has become a focus in cancer immunotherapy 4. Promising advancements have been made by blocking antibodies targeting PD-1, such as nivolumab and pembrolizumab. These antibodies have shown benefits in treating various cancer types such as melanoma, non-small cell lung cancer, and renal cell carcinoma. They achieve this by enhancing T cell function within the tumor microenvironment 5 - 7. These treatments demonstrate how understanding the role of PD-1, in T-cell activity can lead to the development of immunotherapeutic strategies.

Antigen Details

Ligand/Receptor
hPD-L1
NCBI Gene Bank ID
Research Area
Cancer
.
Cell Biology
.
Immuno-Oncology
.
Immunology
.
Signal Transduction

References & Citations

1. Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ. J Clin Pathol. 2018;71(3):189-194.
2. Jiang Y, Chen M, Nie H, Yuan Y. Human Vaccines & Immunotherapeutics. 2019;15(5):1111-1122.
3. Blank C, Gajewski TF, Mackensen A. Cancer Immunol Immunother. 2005;54(4):307-314.
4. Dong Y, Sun Q, Zhang X. Oncotarget. 2017;8(2):2171-2186.
5. Homet Moreno B, Parisi G, Robert L, Ribas A. Semin Oncol. 2015;42(3):466-473.
6. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Trends Mol Med. 2015;21(1):24-33.
7. McDermott J, Jimeno A. Drugs Today (Barc). 2015;51(1):7-20.
Indirect Elisa Protocol
FA
SDS-PAGE
General Western Blot Protocol
Products are for research use only. Not for use in diagnostic or therapeutic procedures.